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Abstract This study was done to investigate the influence of 
Gram-negative and Gram-positive sepsis on the expression of the 
three isoforms of nitric oxide synthase (NOS) gene in rat liver 
and kidney. Male Sprague-Dawley rats were treated with 
lipopolysaccharide (LPS, 10 mg/kg i.v.) as an in vivo model for 
Gram-negative sepsis or lipoteichoic acid (LTA, 10 mg/kg i.v.) as 
an in vivo model for Gram-positive sepsis. Animals were killed 
12 h and 24 h after i.v. treatment. NOS mRNA of the three 
isoforms was determined by RNase protection assay. NOS II 
gene expression was strongly induced after LPS or LTA 
treatment in rat liver and kidney, indicating the efficacy of this 
treatment to induce sepsis. We found no change of NOS I gene 
expression after LPS or LTA injection in rat liver and kidney. 
NOS III gene expression was increased about 8-fold 12 h and 
about 5-fold 24 h after induction of sepsis in the rat liver whereas 
in the kidney there was no significant increase in NOS III gene 
expression. After correction for length NOS III mRNA was 
about 4- and 40-fold more abundant 12 h and 24 h after LPS 
treatment than NOS II mRNA in the liver, respectively. Twelve 
and 24 h after LTA treatment NOS III mRNA was about 18-
and 140-fold more abundant than NOS II in the liver. These 
findings suggest that NOS III is an even more potent source of 
NO than NOS II in the liver after stimulation with LPS or LTA. 
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1. Introduction 
Nitric oxide (NO) is known to play an important role in 
acute inflammation or sepsis. NO is produced by three iso-
forms of NO synthases (NOS I, II and III). The isozymes of 
NOS are classified in two types: Ca2+-dependent and Ca2+-
independent. The Ca2+-dependent isoforms I and III are so 
far reported to be constitutive whereas the Ca2+-independent 
isoform II is inducible. It is the isoform II also termed iNOS 
that is known to be predominant active during inflammation 
[1]. NOS isoform I also named ncNOS has not yet been re-
ported to be regulated by inflammatory stimuli. There is still 
confusion concerning the role of NOS isoform III also known 
as ecNOS during sepsis. Oguchi et al. reported in 1992 the 
existence of a novel and distinct Ca2+-dependent isozyme of 
NOS that is inducible by i.v. injection of LPS [2]. They found 
increased levels of this distinct NOS mRNA in various organs 
whereas it is not yet clear whether this thus reported novel 
NOS is an enzymatically active degradation product of indu-
cible NOS isoform. On the other hand, NOS III mRNA has 
been reported to be down-regulated by TNF-oc [3-5] or LPS 
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[6,7]. In view of these findings it appeared reasonable to us to 
investigate more systematically the expression of the three iso-
forms of NOS during sepsis. To this end, we injected animals 
LPS (10 mg/kg i.v.) as an in vivo model of Gram-negative 
sepsis or LTA (10 mg/kg) as an in vivo model for Gram-
positive sepsis. mRNA levels for NOS I, NOS II and NOS III 
in the rat liver and kidney before and 12 h and 24 h after 
injection of LPS or LTA were determined by specific ribonu-
clease (RNase) protection. We compared the effects on the 
constitutively expressed isoforms of NOS (NOS I and III) 
with those on the expression of NOS isoform II, which is 
generally considered to be up-regulated during inflammation. 
There was no NOS I mRNA detectable in the liver before and 
after LPS or LTA treatment and there was no change of 
NOS I gene expression in the kidney during sepsis treatment. 
As expected NOS II gene expression was strongly induced 
after LPS or LTA injection. The most striking finding was 
that NOS III gene expression was up-regulated in the liver 
but not in the kidney after treatment with both LPS or 
LTA. This NOS III isozyme that has so far been reported 
to be constitutively expressed seems to be inducible in the liver 
but not in the kidney by injection of LPS or LTA and appears 
to be an even more potent source of NO than NOS II in the 
liver. 
2. Materials and methods 
2.1. Animal experiments 
All animal experiments were conducted in accordance with the Na-
tional Institute of Health Guide for the Care and Use of Laboratory 
Animals and the German Law on the Protection for Animals. 
Male Sprague-Dawley rats (300-350 g) that had free access to food 
and water were used for the experiments. Also, during the experi-
ments, the animals had free access to food and water. Thereafter, 
different treatment groups were examined: (1) control animals receiv-
ing 2 ml of Ringer's solution i.v. (n = 6); (2) animals treated with LPS 
(from Escherichia coli; serotype 0111 :B4; Sigma) 10 mg/kg i.v. and 
killed 12 h (n = 6) and 24 h (n = 6) after LPS treatment; (3) animals 
treated with LTA (from Staphylococcus aureus; Sigma) 10 mg/kg i.v. 
and killed 12 h (n = 6) and 24 h (n = 6) after LTA treatment. 
For i.v. injection the animals were anesthetized for 15 min with 
isoflurane under controlled ventilation with a face mask. Therefore 
a Trajan 808 with a connected vaporizer (Drager, Liibeck) and a 
ventilation pump (Rhema Electronics, Hofheim) were used. 
At the end of the experiments, animals were killed by decapitation 
during isoflurane anesthesia, blood and urine were collected and or-
gans were rapidly extirpated, weighed, frozen in liquid nitrogen and 
stored at —80°C until RNA extraction. 
2.2. Extraction of RNA 
Total RNA was extracted from the organs, which were stored at 
—80°C, according to the protocol of Chomczynski and Sacchi [8] by 
homogenization in Solution D (guanidine thiocyanate (4 M) contain-
ing 0.5% 7V-lauryl-sarcosinate, 10 mM ethylenediaminetetraacetic acid 
(EDTA), 25 mM sodium citrate and 700 mM pi-mercaptoethanol) 
using a polytron homogenizer. Sequentially, 1 ml of 2 M sodium 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97 )00835- l 
512 
acetate (pH 4), 10 ml of phenol (water saturated) and 2 ml of chloro-
form were added to the homogenate, with thorough mixing after the 
addition of each reagent. After cooling on ice for 15 min, samples 
were centrifuged at lOOOOXg for 15 min at 4°C. RNA in the super-
natant was precipitated with an equal volume of isopropanol at 
—20°C for at least 1 h. After centrifugation, RNA pellets were resus-
pended in 0.5 ml of solution D, again precipitated with an equal 
volume of isopropanol at —20°C and RNA pellets were finally dis-
solved in diethylpyrocarbonate-treated water and stored at —80°C till 
further processing in RNase protection assays. 
2.3. Determination of NOS I, NOS II and NOS III mRNA by RNase 
protection assay 
The abundance of NOS I, NOS II and NOS III mRNA in total 
RNA isolated from the organs was determined by RNase protection 
assay as described for NOS I [9]. A NOS I cRNA probe containing 
324 bp of the NOS I antisense sequence was generated from a pAM18 
vector carrying a HincWKpnl restriction fragment of NOS I cDNA 
by transcription with SP6 RNA polymerase (Amersham International, 
UK). The NOS II and NOS III cRNA probes containing a 518 bp 
insert and a 184 bp insert, respectively, were generated from a pGEM-
4Z vector carrying a BamHLIEcoKl restriction fragment of NOS II 
cDNA and a pGEM-4Z vector carrying a Kpnl/Pstl restriction frag-
ment of NOS III cDNA, respectively. Transcripts were continuously 
labeled with [32P]GTP (410 Ci/mmol or 15.17 TBq/mmol; Amersham 
International) and purified on a Sephadex G50 spun column. For 
hybridization total RNA was dissolved in a buffer containing 80% 
formamide, 40 mM piperazine, JV,7V'-bis(2-ethane sulphonic acid) 
400 mM NaCl, 1 mM EDTA (pH 8). 100 ug of total RNA were 
hybridized in a volume of 50 ul at 60°C for 12 h with each 5X105 
cpm radiolabeled NOS I, NOS III and NOS II probe, respectively. 
RNase digestion with RNase A and Tl was carried out at 20°C for 
30 min and terminated by incubation with proteinase K (1 mg/ml) and 
sodium dodecyl sulphate (SDS 0.4%) at 37°C for 30 min. 
Protected NOS I, NOS II and NOS III mRNA fragments were 
purified by phenol/chloroform extraction, ethanol precipitation and 
subsequent electrophoresis on a denaturing 6% polyacrylamide gel. 
After autoradiography of the dried gel at —80°C for 1 day, bands 
were excised from the gel and radioactivity was counted with a liquid 
scintillation counter (1500 CarbTm, Pachard Instrument Company, 
Downers Grove, IL). To estimate the relative proportion of NOS I, 
NOS II and NOS III mRNA in the different organs from the protec-
tion assays, the relative lengths of the protected fragments were taken 
into account. 
2.4. Statistics 
The ANOVA test was used for calculation of statistical significance 
and P<0.05 was considered significant. 
3. Results 
3.1. NOS I gene expression before and after treatment with 
LPS or LTA 
In the liver NOS I mRNA was not detectable either in the 
control group or after treatment with LPS or LTA. 
In the kidney NOS I mRNA was detectable (0.5 ± 
0.03 cpm/ug RNA) but there was no significant change in 
NOS I gene expression 12 h or 24 h after LPS or LTA treat-
ment (Fig. 1). 
3.2. NOS II gene expression before and after treatment with 
LPS or LTA 
In the liver NOS II mRNA was not detectable in normal 
rats. Injection of LPS resulted in a time-dependent increase in 
NOS II gene expression (Fig. 2). NOS II mRNA was strongly 
elevated 12 h after injection of LPS (2.6±0.2 cpm/ug RNA) 
and was decreased to 5% of the 12 h level at 24 h after LPS 
treatment (0.14 ±0.02 cpm/ug RNA). Injection of LTA re-
sulted also in a time-dependent increase in NOS II gene ex-
pression whereas the increase was smaller than after LPS 
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Fig. 1. Effects of LPS (10 mg/kg) and LTA (10 mg/kg) on NOS I 
mRNA levels in rat liver and kidney 12 h and 24 h after i.v. injec-
tion. Total RNA (100 u.g) were assayed for NOS I and hybridiza-
tion signal for NOS I mRNA is given per ug RNA. Data are means 
± SE of six animals in each group. 
treatment. The decrease in NOS II gene expression between 
12 h and 24 h after LTA treatment was smaller than after LPS 
treatment (0.47 ±0.03 cpm/ug RNA after 12 h; 0.04 ± 
0.005 cpm/ug RNA after 24 h). 
In the kidney NOS II mRNA was also not detectable in 
normal rats. NOS II gene expression was also strongly in-
duced 12 h after injection of LPS (0.67 ±0.08 cpm/ug RNA) 
and was decreased to about 15% of the 12 h level at 24 h after 
LPS treatment (0.10 ±0.015 cpm/ug RNA). Injection of LTA 
resulted also in a smaller, time-dependent increase in NOS II 
gene expression whereas the decrease between 12 h and 24 h 
after LTA treatment was also smaller than after LPS treat-
ment (0.14 ±0.015 cpm/ug RNA after 12 h; 0.05 ±0.006 cpm/ 
ug RNA after 24 h). 
3.3. NOS III gene expression before and after treatment with 
LPS or LTA 
As shown in Fig. 3 NOS III mRNA was detectable in the 
liver of normal rats (1.2 ±0.1 cpm/ug RNA). NOS III mRNA 
was increased about 8-fold 12 h after LPS treatment (10 ± 
1.1 cpm/ug RNA) and decreased to about 60% of the 12 h 
level at 24 h after LPS treatment (6.0 ±0.3 cpm/ug RNA). 
Injection of LTA resulted in a similar increase in NOS III 
gene expression whereas the increase tended to be smaller 
(8.6±0.8 cpm/ug RNA after 12 h; 5.7±0.3 cpm/ug RNA 
after 24 h). 
In the kidney NOS III mRNA was detectable in normal 
rats (6.4 ±0.5 cpm/ug RNA) but there was no significant in-
crease in NOS HI gene expression either after LPS or LTA 
treatment. 
4. Discussion 
The aim of this study was to investigate the influence of 
Gram-negative and Gram-positive sepsis on the gene expres-
sion of NOS isoforms I and III in rat liver and kidney and to 
compare these effects with those on the expression of NOS 
isoform II, which is generally considered to be up-regulated 
during inflammation. Our findings show that NOS I gene is 
already substantially expressed in the kidney but not in the 
liver of normal animals. NOS II mRNA was not detectable in 
the liver and kidney of normal animals whereas NOS III gene 
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is expressed in the liver and kidney of normal rats. NOS III 
mRNA was more abundant in the kidney than in the liver. 
These findings are in accordance to the results of previous 
studies [9-12]. 
To induce sepsis, we used two manoeuvres, namely i.v. in-
jection of LPS (10 mg/kg) for induction of Gram-negative 
sepsis and i.v. injection of LTA for induction of Gram-pos-
itive sepsis [13]. These two manoeuvres caused a time-depend-
ent stimulation of NOS II gene expression in the liver and 
kidney, whereas up-regulation of NOS II mRNA was stronger 
after LPS treatment than after LTA treatment. It is well es-
tablished that bacterial lipopolysaccharide induces widespread 
in vivo tissue expression of NOS II mRNA [10]. For LTA 
there are few studies reported so far concerning NOS II. It 
has been observed that LTA from Streptococcus viridans pro-
vokes the accumulation of NOS II mRNA in macrophages 
[13]. It has also been noticed that NOS II protein expression 
is increased by LTA from Staphylococcus aureus in the rat 
lung [14] and in macrophages [15]. In vitro analysis showed 
that cyclic GMP levels were elevated in vascular smooth 
muscle cells [16] and endothelium-free aortic rings [17] after 
incubation with LTA from Staphylococcus aureus. There is no 
prior investigation concerning the expression of NOS II 
mRNA in the rat liver and kidney after injection of LTA. 
Our findings show that injection of LPS or LTA has no 
significant effect on NOS I gene expression in rat kidney 
12 h and 24 h after injection. In the rat liver NOS I mRNA 
was not detectable before and after injection of LPS or LTA. 
Little information is available on the regulation of NOS I 
expression. There is evidence from structural investigations 
that the NOS I gene may be transcriptionally regulated [18]. 
For the rat brain it has been observed in vivo that NOS I 
mRNA is down-regulated 4 h after i.p. injection of 15 mg/ 
kg LPS [17]. No previous study is accessible reporting a 
change in NOS I gene expression during sepsis in rat liver 
or kidney. 
This study demonstrates that NOS III gene expression is 
induced in the liver of rats treated with LPS or LTA. There 
was no significant increase in NOS III gene expression in the 
kidney after LPS or LTA treatment. The NOS isoform III is 






Fig. 2. Effects of LPS (10 mg/kg) and LTA (10 mg/kg) on NOS II 
mRNA levels in rat liver and kidney 12 h and 24 h after i.v. injec-
tion. Total RNA (100 ug) were assayed for NOS II and hybridiza-
tion signal for NOS II mRNA is given per |_ig RNA. Data are 
means ±SE of six animals in each group. 'P<0.01 vs. 24 h. 
**P<0.01 vs. LTA. 
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Fig. 3. Effects of LPS (10 mg/kg) and LTA (10 mg/kg) on NOS III 
mRNA levels in rat liver and kidney 12 h and 24 h after i.v. injec-
tion. Total RNA (100 ug) were assayed for NOS III and hybridiza-
tion signal for NOS III mRNA is given per u,g RNA. Data are 
means ±SE of six animals in each group. *P<0.01 vs. control (0 h). 
**P<0.01 vs. 24 h. 
to be constitutively expressed. The NOS III promoter is 
known to be 'TATA-less' and exhibits promoter elements 
consistent with a constitutively expressed gene [19]. Recent 
studies have shown that the NOS III gene is actively regulated 
in response to various physiological or pathophysiological 
stimuli [3,20,21]. This is consistent with the finding that the 
5'-flanking region of NOS III gene contains putative shear 
stress, AP-1, AP-2, NF-1 heavy metal, acute-phase response, 
and sterol-regulatory cis-acting DNA elements [19,22,23]. 
Oguchi et al. reported the existence of a novel and distinct 
Ca2+-dependent isozyme of NOS that is inducible by i.v. in-
jection of LPS [2]. They found increased levels of this distinct 
NOS mRNA in various organs (liver, lung, spleen, colon, 
ileum) by Northern blot analysis. As mentioned above West-
ern blot analysis of this induced NOS showed cross-reactivity 
with the inducible NOS from rat liver. It is not yet clear 
whether this thus reported novel NOS is an enzymatically 
active degradation product of inducible NOS isoform. The 
findings of Oguchi et al. suggest that there might be another 
source of NO besides NOS II during sepsis. The results of the 
present study show that NOS III is another potent source of 
NO besides NOS II in rat liver during sepsis. 
NO plays an important role in the control of vascular tone 
[24] and it has been established that NO has antimicrobial [25] 
and platelet inhibiting activity [26]. Consequently in the con-
dition of septic shock the controlled over production of NO 
by NOS II and NOS III in the liver could be of relevance for 
maintaining an adequate blood flow and for inhibition of 
intravascular coagulation and also for antimicrobial defense. 
It has been reported that NOS III mRNA was down-regu-
lated in bovine coronary venular endothelial cells by LPS 
whereas the mechanism of action was ascribed to a post-tran-
scriptional regulation via destabilization or increased degra-
dation of NOS III mRNA with no effect on transcription [6]. 
Liu et al. found down-regulation of NOS III mRNA rat lung, 
heart and aorta after injection of LPS (15 mg/kg i.p.) by 
Northern blot analysis [7]. 
These findings are not in contrast to our results. Whether 
the effect of LPS or LTA on NOS III gene expression is 
specific to the liver remains to be investigated. Further explo-
rations are necessary to characterize this NOS III isoform in 
the liver. 
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